The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Relmada expects to initiate its Phase 3 program in the first half of 2026
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Subscribe To Our Newsletter & Stay Updated
